| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner | 2026-06-25 | 50,055 | $4.12 | $206.08kBuy |
| Kathleen Borthwick | CFO | 2026-01-08 | 2,062 | $18.44 | $38.02kSell |
| William Chou | PRESIDENT AND CEO | 2026-01-08 | 4,076 | $18.44 | $75.16kSell |
| Lynx1 Capital Management LP | 10% Owner | 2025-09-15 | 11,900 | $6.99 | $83.17kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-09-12 | 19,783 | $6.99 | $138.30kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-09-11 | 325 | $6.96 | $2.26kBuy |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Orbimed Advisors LLC | 374.51% | 12,013,666 | $55.38M | Insider |
| Frazier Life Sciences IX LP | 156.16% | 5,009,219 | $23.09M | Insider |
| Patrick J. Heron | 156.16% | 5,009,219 | $23.09M | Insider |
| Versant Venture Capital VI LP | 154.62% | 4,959,769 | $22.86M | Insider |
| Thomas Woiwode | 154.62% | 4,959,769 | $22.86M | Insider |
| Liam Ratcliffe | 81.66% | 2,619,430 | $12.08M | Insider |
| Lynx1 Capital Management LP | 21.00% | 673,759 | $3.11M | Insider |
| Stephen P. Squinto | 20.84% | 668,575 | $3.08M | Insider |
| Tadataka Yamada | 20.45% | 656,149 | $3.02M | Insider |
| Lynx1 Capital Management LP | 19.44% | 623,704 | $2.88M | Institution |